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Abstract:  
The significance of hepatitis B e-antigen seroclearance (ESC) in the long term is 
not well defined. The current study aimed to determine the clinical outcomes, 
the factors and predictive scores for hepatocellular carcinoma (HCC) and 
hepatitis B surface antigen (HBsAg) seroclearance of a large cohort of patients 
undergoing ESC. Patients with documented ESC were followed up 3-6 monthly. 
Baseline characteristics and longitudinal laboratory results were recorded.  
Predictive scores for HCC (HCC-ESC) and HBsAg seroclearance (HBsAg-ESC) 
were derived from multivariate Cox regression models. A total of 723 patients 
underwent ESC with a median ESC age and follow-up of 36.0 and 18.3 years 
respectively. Only 3.5% and 3.0% had persistently normal ALT and HBV DNA 
<2logs IU/mL respectively after ESC. For patients with 100%, 100-90%, 90-50%, 
50-10%, 10-0%, and 0% normal ALT after HBeAg seroclearance, the rate of HCC 
was 4.3%, 2.2%, 3.6%, 3.9%, 17.3%, and 37.2% at 20 years after ESC 
respectively (p<0.001). At 20 years after ESC, the cumulative incidence of HCC 
and HBsAg seroclearance was 7.9% and 13.5% respectively, with an overall 
survival of 91.5%. ESC age, male sex, cirrhosis, hypoalbuminemia, viral load, and 
ALT were significant factors for HCC, whereas ESC age, male sex, viral load, and 
antiviral therapy were significant factors for HBsAg seroclearance. The AUROC 
for HCC-ESC and HBsAg-ESC scores to predict HCC and HBsAg seroclearance at 
20 years after ESC was 0.92 and 0.74 respectively. Conclusions: Male gender, 
older age at ESC, ALT, and higher level of HBV DNA were associated with higher 
rates of HCC after ESC. HCC-ESC and HBsAg-ESC predictive scores can determine 
the likelihood of developing HCC and achieving HBsAg seroclearance.   
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With an estimated 257 to 284 million people infected with the hepatitis B virus 
(HBV), chronic hepatitis B (CHB) continues to be a significant health burden in 
many parts of the world, where infection remains at an endemic rate (1, 2). 
There are typically several different phases in the natural history of CHB 
infection (3, 4). The hepatitis B e-antigen (HBeAg)-positive chronic HBV infection 
is characterized by a positive HBeAg, very high viral load, and with minimal to no 
hepatitic activity (5, 6). In the HBeAg-positive CHB phase, the patients are still 
HBeAg positive, but with fluctuating viral load and liver enzymes indicating 
underlying hepatic inflammation (7). Eventually, patients will undergo HBeAg 
seroclearance (ESC) to enter the HBeAg-negative chronic HBV infection phase, 
where the viral load is modest to low with minimal to no clinical evidence of 
hepatitis (8). In the HBeAg-negative CHB phase, patients may have fluctuating 
moderate-to-high HBV DNA levels and fluctuating or persistently elevated ALT 
levels. The hepatitis B surface antigen (HBsAg)-negative phase is characterized 
by loss of HBsAg with or without the development of anti-HBs. 
 
The important milestone of ESC has traditionally been viewed as a treatment 
endpoint and a measurement of treatment success for HBeAg positive subjects 
(9). It is still regarded by major regional treatment guidelines as a parameter for 
stopping antiviral therapy. However, a significant proportion of patients who 
undergo ESC may progress to the HBeAg negative CHB phase, with high 
fluctuating viral load and evidence of active hepatitis (10, 11). Furthermore, a 
significant proportion of patients will develop liver cirrhosis and hepatocellular 
carcinoma (HCC) after ESC even with low HBV DNA levels and minimally raised 
ALT levels while remaining HBeAg negative (12).  
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Therefore, despite being an important milestone in the natural history of CHB 
infection, the significant and clinical events after ESC need to be defined more 
accurately. The current study aimed to determine the clinical outcomes of a large 
cohort of patients who had undergone ESC, and to determine factors associated 
with hepatitis flares, persistent viremia, development of HCC, and mortality after 
ESC.  We also aimed to derive predictive scores for the probability of HCC and 
HBsAg seroclearance using this large cohort based study.   
 
Patients & Methods: 
As part of the Hong Kong Chronic Liver Disease study, all records of patients 
seen at the Liver and Hepatitis Clinics at Queen Mary Hospital, Hong Kong, from 
January to December 2004 were reviewed (13). Of the 6,430 patients, 6,106 had 
evidence of chronic liver disease, of which 5,460 had CHB. Those that had 
significant alcoholic intake and hepatitis C infection or other chronic liver 
diseases were excluded. In 2007, patients that were still actively followed up 
were reviewed for evidence of ESC during their follow-up period for recruitment 
into the current study. Of the initial 5,460 CHB patients, 871 were lost to follow 
up or referred out upon requests from patients because of geographical reasons. 
Another 39 patients passed away, of which 5 were HBeAg-positive at 
presentation (and remained positive at the time of death), and 34 were HBeAg-
negative at presentation. A total of 4,550 patients were actively followed up in 
2007, of which 3,204 were already HBeAg-negative at the time of first 
presentation (without documented time of ESC). In the remaining 1,346 patients 
who were HBeAg-positive at the time of presentation, 623 patients remained 
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HBeAg-positive at the time of study recruitment. The remaining 723 HBeAg-
positive patients underwent ESC during the follow-up period and were included 
in the current study. The flow of patients is shown in figure 1.  
 
For the dataset, basic demographic parameters, and longitudinal laboratory 
results including routine liver biochemistry and HBV serology were recorded. 
Clinical outcomes including hepatitis flares, the development of HCC, HBsAg 
seroclearance, and liver-related mortality were also recorded.  
 
Patient monitoring 
Patients with CHB were followed up regularly at a 3-6 monthly interval, with 
routine liver biochemistry, HBV serology, and alpha-fetoprotein (AFP). Patients 
were also advised to have regular ultrasound surveillance at 6 monthly intervals. 
Cirrhosis was defined clinically on ultrasonographical features including small-
sized liver, nodular surface, and splenomegaly, with or without the 
manifestations of portal hypertension. 
 
Viral load 
HBV DNA levels were measured using the Cobas Taqman assays (Roche 
Diagnostics, Branchburg, NJ), with a lower limit of detection (LLOD) of 12 IU/mL 
initially and 20 IU/mL subsequently as provided by the manufacturer in the later 
version of the test, with the latter adopted for statistical analysis. Measurements 
of HBV DNA were not routinely funded, and performed at the discretion of the 
attending physicians. For this study, only HBV DNA measurements performed in 
treatment-naïve patients or prior to commencing antiviral therapy were 
Page 6 of 36
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
included. On-treatment HBV DNA measurements were not included for analysis, 
and were censored at the time of starting antiviral therapy.  
 
Core promoter mutation analysis and genotyping 
The core promoter mutation and not precore mutation has been shown 
previously to be associated with adverse clinical significant outcomes (14, 15). 
Therefore, only the core promoter mutation and genotype was determined on 
available samples at 3-24 months after ESC. The method of HBV core promoter 
detection was described in our previous study (16). The presence of core 
promoter mutations was denoted by the presence of the A1762T-G1764A double 
mutations. Genotyping was performed by phylogenetic comparison of the 
sequences from these amplicons with HBV reference sequences using the NCBI 
HBV genotyping tools (17).  
 
Antiviral therapy 
As the antiviral medications were largely self-funded prior to 2009, the decision 
for treatment and the type of antiviral agent used was at the discretion of the 
patients. The mainstay of therapy was oral nucleos(t)ide analogs, with the use of 
interferon being mostly at the time prior to the availability of oral antiviral 
therapy. As a result, only 2 patients received pegylated interferon. The 
recommendation to treat was based on available treatment guidelines at the 
time(18, 19), and later from the major regional guidelines (20), and also from 
available clinical trials during the study period. Patients were continued on 
antiviral therapy after ESC, and cessation of therapy was at the patient’s own 
discretion. If the patients do decide to stop therapy, it will be on the 
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recommendation of at least 1 year of consolidative therapy after ESC together 
with persistently undetectable viral load and normal ALT.  
 
This study was approved by the Institutional Review Board/Ethics Committee of 
The University of Hong Kong/Western Cluster of Hospital Authority, Hong Kong. 
As this was a review of clinical data without intervention, the need for informed 
consent was waived. The study protocol conformed to the ethical guidelines of 
the 1975 Declaration of Helsinki.  
 
Statistical analysis 
All statistical analyses were performed using SPSS and R version 3.2.3 (R 
Foundation for Statistical Computing) statistical software. Mann-Whitney test 
was used for comparing two continuous variables with skewed distribution. 
Kruskal-Wallis test was used for comparison between three or more variables. 
The cumulative incidence of liver-related events was analyzed using the Kaplan-
Meier method, with log-rank testing between different variables.  A P value of 
<0.05 was considered statistically significant. 
 
Predictive scores for the two outcomes (HCC and HBsAg seroclearance) were 
formulated as a weighted sum of the significant independent variables. The 
weights were assigned based on the corresponding estimated coefficients 
derived from multivariable Cox regression models after being divided by the 
smallest coefficient and rounded to the nearest integer. The predictive accuracy 
of the two scores for predicting the development of the corresponding outcomes 
at 5, 10 and 20 years was assessed by estimating a time-dependent receiver 
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operating characteristics curve (ROC) by the nearest neighbor estimation 
method. The area under ROC (AUROC) was then calculated with the 95% 
confidence interval (95% CI) obtained by sampling the original group of patients 
for 1000 bootstrap samples. To assess the performance of the two scores in new 
data, they were assessed by the leave-one-out cross-validation (LOOCV). In brief, 
one patient was dropped from the cohort each time to re-determine the weights 
for calculating the scores for that particular patient, and the process was 
repeated for other patients. Cut-off values for predicting HCC and HBsAg 
seroclearance at 5, 10 and 20 years were derived by maximizing the Youden 
index (sensitivity – [1 – specificity]) from the time-dependent ROC analysis. 
Predictive accuracy using the optimal cut-off value at each time point was 
assessed by the sensitivity, specificity, predictive values and likelihood ratios. 
Similarly, the 95% CIs were derived by 1000 bootstrap samples, and the cut-off 
values were assessed by the LOOCV (supplementary table 1).  
 
Results 
A total of 723 patients were included (figure 1). At the time of initial 
consultation, the median age was 32 years (range, 18-83), with a median age of 
ESC of 36 years (range, 19-85). The median follow-up length was 18.3 years 
(range, 2.8-32.9), totaling 13,827 patient-years. The patient characteristics and 
laboratory values at the time of ESC are summarized in table 1. 
 
During the entire follow-up period, 296 (40.9%) patients remained treatment-
naïve, while the remaining 427 (59.1%) received antiviral therapy. Fifty (7%) 
patients received antiviral therapy prior to ESC (but were not on therapy at the 
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time of ESC), of which 41 had interferon-based therapy, and 10 patients received 
lamivudine for a limited duration. Of the 41 patients who received interferon 
therapy prior to ESC, only 1 patient received pegylated interferon, and 7 patients 
achieved ESC within 1 year after stopping therapy.  
 
One hundred and sixty nine (23%) were on therapy at the time of ESC, of which 
the majority was receiving lamivudine.  After ESC, 231 (32%) required 
commencement of antiviral therapy, of which some had already received therapy 
prior to HBeAg seroclearance. There were different time-points for the 
resumption of therapy, and some patients may have received more than one type 
of antiviral therapy. Therefore the cumulative number of treated patients at 
different time points might be higher than the absolute number of patients 
receiving antiviral therapy. A summary of antiviral therapy in this cohort is 
shown in table 2. 
 
Serum ALT levels 
The longitudinal profiles of all patients were analyzed, with a total pooled 
sample of 32,222 results. The upper limit of normal (ULN) ALT was defined as 
according to the American Association for the Study of Liver Diseases (AASLD) 
recommendations of 30 and 19 U/L for males and females respectively (21). 
Only 3.5% had completely normal ALT after ESC, and 10.1% had normal ALT at 
≥90% of the follow-up period after ESC. Conversely, 10.1% had persistently 
elevated ALT after ESC, with 19.4% having abnormal ALT for ≥90% of the follow-
up period (supplementary figure 1A).  
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The patterns of ALT after ESC were divided into four groups, with flares being 
defined as 3x ULN (absolute value: 90 IU/L for male; 57 IU/L for female). This 
cut-off was chosen because the normal ranges provided by the hospital 
laboratory was higher than the AASLD ULN. We regarded those with 2x ULN 
from the hospital laboratory as flares, which approximately equals to 3x ULN 
using the AASLD limits. The groups are defined as follows: 1 = persistently 
normal ALT, 2 = normal ALT with episodes of ALT up to <3x ULN, 3 = normal 
ALT with episodes of ALT ≥3x ULN, and 4 = persistently abnormal ALT. The 
majority of patients had either achieved normal ALT but with evidence of 
episodes of elevated ALT <3x ULN (group 2) and ≥3x ULN (group 3) (42.2% and 
44.3% respectively, supplementary figure 1B). Overall, 73 (10.1%) of patients 
(group 4) did not achieve normal ALT after ESC. 
 
Viral load 
A total of 2,547 HBV DNA measurements were performed in 518 patients. 
Excluding those patients who were already on antiviral therapy at the time of 
ESC, 518/553 (94%) patients had HBV DNA measured after ESC, and 450 (81%) 
had at least two measurements. For those with two or more measurements, only 
149 (33%), 69 (15%), and 13 (3%) had HBV DNA consistently <4 logs, <3 logs, 
and <2 logs IU/mL respectively. In a pooled analysis determining the trend of 
viral load over time, there was no significant difference in the median viral load 
at 1, 2, 3, 4, 5, 5-10, 10-15, 15-20, 20-25, and >25 years after ESC (3.67, 3.62, 
3.52, 3.49, 3.50, 3.47, 3.37, 3.43, 3.21, 3.62, and 3.08 logs IU/mL respectively, 
p=0.116, supplementary figure 2).  
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Hepatocellular carcinoma 
The cumulative incidence of HCC was 0.1%, 2.2%, 4.6%, 7.9% and 8.6% after 1, 
5, 10, 20, and 30 years respectively after ESC, with a total of 44 cases. For 
patients who underwent ESC before age 30, 30-40, and over 40 years of age, the 
cumulative rate of HCC a was 1.2%, 1.6% and 11.7% respectively at 10 years 
post ESC, and 1.2%, 4.9%, and 20% respectively at 20 years post ESC (p< 0.001) 
(fig 2A). The median age of HCC development was 55 years. 
 
To exclude the potential younger age bias for patients undergoing ESC at a 
younger age who might not have been followed up for a sufficiently long period, 
all patients age 50 years or older without liver-related complications at the time 
of last follow up were compared to those who developed HCC.  A total of 413 
non-complicated patients with a median age of 56 (range, 50-92) showed a 
significantly lower age of ESC compared to patients who developed HCC (39 vs 
46 years respectively, p<0.001).  
 
Using the previous ALT group stratification, there was a significantly higher rate 
of HCC for those who have persistently elevated ALT (group 4) (fig 2B). At 20 
years post ESC, the cumulative rate of HCC was 37.2% for ALT group 4, 
compared to 4.3%, 3.4%, and 6.3% for ALT groups 1, 2, and 3 respectively 
(p<0.001). For those with 100%, 100-90%, 90-50%, 50-10%, 10-0%, and 0% 
normal ALT after ESC, the rate of HCC was 4.3%, 2.2%, 3.6%, 3.9%, 17.3%, and 
37.2% at 20 years after ESC respectively, p<0.001, fig 2C).  A significantly higher 
rate of HCC was observed in patients with higher HBV DNA. At 20 years post ESC, 
the rate of HCC was 11.1%, 1.2%, 0%, and 0% for those with HBV DNA >4, <4, <3, 
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and <2 logs IU/mL respectively (p=0.006) (fig 2D). There was a trend towards 
higher rate of HCC at 20 years after ESC for those with core promoter mutation 
compared to those without (10.4% vs 3.7% respectively, =0.051), and higher 
rates observed in genotype C compared to B (9.0% vs 1.4% respectively, 
p=0.048). 
 
After multivariate analysis, age, male sex, cirrhosis, hypoalbuminemia, HBV DNA 
and ALT flares or persistently abnormal ALT remained significant factors for 
HCC development (table 3). The HCC-ESC score to predict the HCC risk for up to 
20 years after ESC was calculated using age (years) + 20 * sex (male=1; 
female=0) + 29 * cirrhosis (presence=1; absence=0) + 5 * DNA (log IU/mL) + 31 * 
ALT group (flares or persistently abnormal ALT=1; otherwise=0) + 23 * 
hypoalbuminemia (<39 g/L, presence=1; absence=0), and with risk shown in fig 
3A. With an optimal cut-off of 129, 121, and 114, the AUROC for predicting 
development of HCC at 5, 10 and 20 years after ESC was 0.95, 0.91, and 0.92 
respectively (table 4).  
 
HBsAg seroclearance 
A total of 63 patients achieved HBsAg seroclearance, of which 46 had evidence of 
HBsAg seroconversion with the development of anti-HBs. The cumulative rate of 
HBsAg seroclearance was 1.1%, 3.3%, 13.5% and 23.4% at 5, 10, 20, and 30 
years after ESC. There was no significant difference in the rate of HBsAg 
seroclearance between those who underwent ESC at age before 30, 30-40, and 
over 40 years (p=0.431). There was a significantly higher rate of HBsAg 
seroclearance for those who did not require oral nucleos(t)ide analog therapy 
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compared to those that received oral therapy  (21.3% vs 4.3% respectively at 20 
years post ESC, p<0.001). This may highlight the fact that those that do not 
require antiviral therapy may intrinsically have a better disease profile with 
more favorable virological and biochemical characteristics.  
 
There was a significantly lower rate of HBsAg seroclearance for those who have 
persistently elevated ALT without achieving normal ALT (fig 4A). At 20 years 
post ESC, the cumulative rate of HBsAg seroclearance was 1.8% for ALT group 4, 
compared to 79.4%, 15.5%, and 9.8% for ALT groups 1, 2, and 3 respectively 
(p<0.001). By stratifying the proportion of normal ALT after ESC, there was a 
stepwise increase in HBsAg seroclearance with increasing percentage of normal 
ALT (fig 4B). For those with persistently normal ALT, 90 to <100%, 50 to <90%, 
10 to <50%, >0 to <10%, and persistently abnormal ALT, the HBsAg 
seroclearance rate was 79.4%, 25.9%, 17.8%, 7.5%, 0%, and 1.8% respectively at 
20 years after ESC (p<0.001, fig 4B). A higher rate of HBsAg seroclearance at 20 
years post ESC was observed for those with core promoter mutation compared 
to those without (20.2% vs 8.2% respectively, p=0.048), with no difference 
observed between genotype B and C.  
 
After multivariate analysis, age, male gender, viral load, and history of antiviral 
therapy remained significant factors associated with HBsAg seroclearance (table 
3). The HBsAg-ESC score to predict HBsAg seroclearance up to 20 years was 
calculated using age (years) + 15 * sex (male=1; female=0) - 6 * DNA (log IU/mL) 
- 40 * history of treatment (presence=1; absence=0), with the chance shown in 
fig 3B). Using optimal cut-offs of 19, 17, and 12 to predict HBsAg seroclearance at 
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5, 10, and 20 years after ESC were associated with an AUROC of 0.88, 0.84, and 
0.74 respectively (table 4).  
 
Survival 
The 5, 10, 20, and 30 year overall survival after ESC was 99.2%, 96.6%, 91.5%, 
and 88.3% respectively. Overall, 23 patients died of liver-related events (19 HCC 
and 4 decompensation), and 5 patients underwent liver transplantation for HCC. 
The cumulative liver-related mortality (including liver transplantation) at 5, 10, 
20, and 30 years after ESC was 0.7%, 2.7%, 4.9%, and 6.5% respectively. Those 
that underwent ESC at age over 40 years had higher liver-related events 
compared to those that seroconverted at 30-40 years and below 30 years (15.7% 
vs 1.7% vs 0.6% respectively at 20 years after ESC, p<0.001, fig 4C).  
 
Higher rates of liver-related mortality/liver transplantation were observed for 
ALT group 4 compared to 1, 2, and 3 (24.4% vs 4.3%, 3.1%, and 2.6% at 20 years 
post ESC respectively, P<0.001, figure 4D) and for those who had persistently 
elevated ALT compared to those who had >0 to <10%, 10 to <50%, 50 to <90%, 
90 to <100%, and persistently normal ALT (25.6% vs 7.1% vs 2.6% vs 1.7% vs 
2.2% vs 4.2% respectively, p<0.001). Significantly higher liver-related events 
were seen in those with cirrhosis compared to non-cirrhotics (24.6% vs 1.5% 
respectively, p<0.001). No difference was observed between patients treated 
with oral nucleos(t)ide analogs compared to those who did not receive oral 
antiviral therapy (p=0.904).  
 
Discussion 
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The current study followed up a large cohort of 723 CHB patients from the time 
of ESC over a long period of up to 30 years, totaling 13,827 patient-years, with 
analysis of over 32,000 longitudinal blood results. Although the majority (88%) 
achieved normalization of ALT (with or without antiviral treatment), only a 
minority (5.3%) maintained persistently normal ALT after ESC. The viral load 
was likewise only low (<4 logs IU/mL) in 34%, with the majority having a higher 
viral load at some points after ESC. The overall proportion receiving antiviral 
therapy was 59.1%, with 31.8% commencing antiviral therapy after ESC. These 
results suggests that even after ESC, the overwhelming majority of patients will 
still have significant viremia and elevated transaminases necessitating antiviral 
therapy. The rate of HCC development is modest (8.6% at 30 years after ESC). 
Higher rates of HCC were observed in patients who were older at the time of ESC, 
had persistent elevated ALT and higher HBV DNA post ESC, or had underlying 
established cirrhosis. The overall rate of HCC should have been higher if there is 
no widespread use of long-term antiviral therapy in CHB patients. This highlights 
the importance of viral suppression with normalization of ALT.  
 
Those with persistently normal ALT after ESC had a much more favorable 
outcome, including a low rate of HCC development, high rate of HBsAg 
seroclearance, and low liver-related mortality (2.9%, 70.3%, and 4.2% 
respectively at 20 years after ESC). In fact, those patients achieving normal ALT 
at some points after ESC (groups 1, 2 and 3) consistently had a more favorable 
outcome with significantly lower rates of HCC and liver-related mortality and 
higher rate of HBsAg seroclearance compared to those patients that never 
achieved normalization of ALT (group 4). The importance of ALT has been 
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established previously in another study of 3,233 patients showing that higher 
levels of ALT were at a greater risk of developing complications in Asian CHB 
patients (22).  
 
Previous studies have also demonstrated the increased risks of developing HCC 
associated with higher levels of HBV DNA, although these studies were based on 
viral load at a single time point in community-based patients not on antiviral 
therapy (23, 24). The current study included patients who required antiviral 
treatment before and/or after ESC, and non-treated patient, within a tertiary 
care setting. In the current study, those with HBV DNA consistently less than 4 
logs IU/mL had a lower rate of HCC development compared to those with levels 
above this threshold. The level of HBV DNA appeared to be stable over time from 
early after ESC to over 25 years. However, this may not be strictly representative 
given that 55.2% were on antiviral therapy at the time of ESC or commenced 
afterwards, and their viral load were censored at the time of antiviral therapy. 
Nevertheless, the study provides a longitudinal picture of viral load without 
treatment after ESC and their association with HCC development and HBsAg 
seroclearance.  
 
After multivariate analysis, older age at ESC, male sex, higher HBV DNA, 
cirrhosis, hypoalbuminemia, and persistently abnormal ALT/flares were 
significant independent predictors for developing HCC. For HBsAg seroclearance, 
older age at ESC, male sex, lower HBV DNA levels and the absence of antiviral 
therapy were significant predictors. The development of the HCC-ESC and 
HBsAg-ESC predictive scores allows long-term risk stratification for patients for 
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up to 20 years, identifying patients with both favorable (HBsAg seroclearance) 
and unfavorable (HCC) profiles. For predicting HCC risk, the score can achieve a 
very high sensitivity and specificity values throughout 5 to 20 years. The high 
NPV, combined with an AUROC of ≥0.91 for up to 20 years after ESC provides 
reassurance for those within the optimal cut-off values, where the risk is 
minimal. Apart from the ESC age and gender, the remaining components of the 
HCC-ESC model are dynamic, and can be calculated accordingly during the follow 
up after ESC. Hence patients may not remain in the low risk category during their 
follow-up period if they develop cirrhosis, significant viremia, or hepatitis.  
In addition to the new HCC-ESC score, the present study is the first to derive the 
HBsAg-ESC predictive score, which has very high sensitivity (100%) and 
specificity (76%) at year 5, and maintaining good accuracy even up to year 20. 
Both scores were validated by the stringent leave-one-out statistical analyses, 
with a high sensitivity and specificity of predictions at 5, 10, and 20 years. This is 
an important finding to allow clinicians and patients to have ideas on their 
chances of HBsAg seroclearance, the best achievable endpoint of treatment to 
date. It has been shown that cessation of treatment in patients on antiviral 
therapy after achieving HBsAg seroclearance was associated with negligible rate 
of viral rebound (25).  
 
There are several limitations of the current study. Firstly, this is an observational 
cohort study and not a randomized controlled study. Therefore untreated 
patients may be biased to have more favorable virological and biochemical 
profile compared to those requiring antiviral therapy. This may account for the 
fact that there was no difference in HCC development between treated and non-
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treated patients, and the higher rate of HBsAg seroclearance observed in non-
treated patients. There was also a paucity of patients treated with pegylated 
interferon. Secondly, viral load was not performed at regular intervals, although 
the majority did have at least one measurement performed. Thirdly, the HBV 
genotype and core promoter mutation were not routinely performed and were 
not available for all patients. The precore mutation was also not performed, 
although previous studies have shown that it was not significantly associated 
with HCC or cirrhosis (14, 15, 26). Fourthly, the definition of cirrhosis was 
defined on ultrasound findings, which may not have identified patients with 
cirrhosis but without overt features on imaging. Finally, the HCC-ESC and HBsAg-
ESC scores were derived in a single cohort. External validation should be 
performed by future studies, with collaboration from different centers to confirm 
the results of the current study.  
 
In conclusion, persistent viremia and elevated ALT remained common after ESC. 
Male gender, older age at ESC, failure to normalize ALT, and higher levels of HBV 
DNA were associated with higher rates of HCC after ESC. The use of the HCC-ESC 
and HBsAg-ESC scores should provide clinicians with new tools to offer more 
guided management for CHB patients.   
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Figure legends: 
Figure 1. Patient flow and inclusion 
 
Figure 2. Cumulative rate of hepatocellular carcinoma according to (A) age of 
HBeAg seroclearance, (B) ALT profile, (C) proportional of normal ALT, and (D) 
HBV DNA levels 
 
Figure 3. Chance of (A) HCC and (B) HBsAg seroclearance at 5, 10, and 20 years 
after HBsAg seroclearance 
 
Figure 4. Rate of HBsAg seroclearance according to (A) ALT profile and (B) 
proportion of normal ALT.  Rate of liver-related mortality/transplantation 
according to (C) age of HBeAg seroclearance, and (D) ALT profile 
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‘Table 1. Patient demographics and laboratory parameters 
Parameter Values 
Cohort number (n) 
Male sex, n(%) 
Age at baseline (years) 
Age at HBeAg seroclearance (years) 
Age at last follow-up (years) 
Length of follow-up (years) 
 
At time of HBeAg seroclearance 
Bilirubin (umol/L) 
Alkaline phosphatase (U/L) 
Gamma-glutamyl transferase (U/L) 
Alanine aminotransferase (U/L) 
















Continuous variables are expressed as median values (range). 
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Table 2. Antiviral therapy use at different phases of chronic hepatitis B 
Treatment time-point and type of therapy Value 
Before HBeAg seroclearance * 
  Total number of patients 
  Interferon-based therapy** 
  Lamivudine 
 
On-treatment during HBeAg seroclearance*** 
  Total number of patients 
  Lamivudine 
  Interferon-based therapy 
  Entecavir 
  Adefovir 
 
After HBeAg seroclearance**** 
  Total number of patients 
  Entecavir 
  Lamivudine 
  Telbivudine 
  Adefovir 




















* Antiviral therapy given before but not at the time of HBeAg seroclearance  
** 7 patients achieved HBeAg seroclearance within 1 year of stopping interferon 
*** Antiviral therapy given before and during the time of HBeAg seroclearance 
**** Antiviral therapy given after HBeAg seroclearance
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Table 3. Multivariate analysis of factors associated with HCC and HBsAg 
seroclearance 
Parameter Adjusted HR 95% CI P value 
Development of HCC 




HBV DNA (log) 
Normal with flares or 
persistently abnormal ALT 
 
HBsAg seroclearance 
Age at HBeAg seroclearance 
Male sex 
HBV DNA (log) 
















1.03 – 1.10 
1.22 – 9.41 
2.55 – 14.43 
1.53 – 10.96 
1.01 – 1.73 




1.01 – 1.09 
1.02 1.02 – 4.03 
1.03 0.61 – 0.92 
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Table 4. Performance of risk scores for HCC and HBsAg seroclearance up to 20 
years after HBeAg seroclearance 

















































































* HCC risk = age (years) + 20 * sex (male = 1; female = 0) + 29 * cirrhosis 
(presence =1; absence = 0) + 5 * DNA (in log IU/mL) + 31 * ALT group (flares or 
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persistently abnormal ALT = 1; otherwise = 0) + 23 * hypoalbuminemia 
(presence =1; absence = 0) 
** HBsAg seroclearance = age (years) + 15 * sex (male = 1; female = 0) - 6 * DNA 
(in log IU/mL) - 40 * history of treatment (presence =1; absence = 0) 
 AUROC = area under receiver operating characteristic; NLR = negative 
likelihood ratio; NPV = negative predictive value; PLR = positive likelihood ratio; 
PPV = positive predictive value 
Page 27 of 36
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.




Died (n=39)  
5 HBeAg+, 34 HBeAg- 
Lost to follow-up/referred 
out/below age 18 at 
presentation (n=871) 
HBeAg+ without  
HBeAg seroclearance 
n=623 
HBeAg- at  presentation 
n=3204 
HBeAg+ with documented 
HBeAg seroclearance 
n=723 
Other liver diagnosis (n=646) 
CHB patients with active 
follow-up 
n=4550 
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0                   5                  10                 15                 20                 25                 30 
Time after HBeAg seroclearance (years) 
HBeAg seroclearance <30 years 
HBeAg seroclearance 30-40 years 
HBeAg seroclearance >45 years 
P<0.001 
Numbers at risk 




221                    206                       172                       66                        18                         4  
324                    318                       299                      193                       80                        26                        1 
178                    169                       158                      106                       46                        26                        2   
Proportion of normal ALT 
Group 1: 100% 
Group 2: ≥90% to <100% 
Group 3: ≥50% to <90% 
Group 4. ≥10% to <50% 
Group 5: >0% to <10% 
Group 6: 0% Group 6 
Group 5 
Group 1 Group 4 
Group 3 
Group 2 
Numbers at risk 






 0                      5                    10                    15                   20                    25                   30 
Time after HBeAg seroclearance (years) 
 25                       22                       19                        9                          3                           1 
 48                       47                       42                       27                         9                           3                         1 
283                     279                     263                    146                       56                         2 5                        1 
227                     223                     204                    123                       53                         1 9                        1               
 67                       66                       56                       37                        17                          8 
 73                       56                       45                       24                         6        
P<0.001 
  0                       5                     10                     15                    20                     25                    30 
Time after HBeAg seroclearance (years) 
HBV DNA groups 
Group 1: <2 logs IU/mL 
Group 2: <3 logs IU/mL 
Group 3: <4 logs IU/mL 
Group 4: ≥4 logs IU/mL 
p=0.006 
Numbers at risk 




 27                          25                        24                         16                        11                          5   
 58                          57                        53                         34                        11                          6 
 90                          89                        80                         50                        20                          5                          2 




Group 1. Normal ALT 
Group 2. Normal ALT & ALT <3x ULN 
Group 3. Normal ALT with flares  






0                    5                   10                  15                  20                  25                  30 
Time after HBeAg seroclearance (years) 
Numbers at risk 




 25                        22                         19                          9                            3                             1 
305                      298                       263                      140                         46                           19                         3 
320                      317                       303                      193                         89                           36     
 73                        56                          45                        24                           6                        
A B 
C D 
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  0                       5                     10                     15                    20                     25                    30 
Time after HBeAg seroclearance (years) 
Group 1. Normal ALT 
Group 2. Normal ALT & ALT <3x ULN 
Group 3. Normal ALT with flares  






Numbers at risk 




 25                         20                         15                          5                            1                              
305                      293                       245                      125                         35                           12                         1 
320                      317                       297                      180                         74                           28     
 73                         59                         50                         24                           4                        
Numbers at risk 






 0                      5                    10                  15                   20                    25                   30 
Time after HBeAg seroclearance (years) 
 25                       20                       15                        5                          1                            
 48                       44                       34                       20                         5                                                     
283                     276                     247                    130                       41                       17                         
227                     224                     200                    116                       44                       16                        1               
 67                       66                       56                       37                        17                          8 
 73                       59                       50                       24                         4        
Proportion of normal ALT 
Group 1: 100% 
Group 2: ≥90% to <100% 
Group 3: ≥50% to <90% 
Group 4. ≥10% to <50% 
Group 5: >0% to <10% 








  0                   5                  10                 15                 20                 25                 30 
Time after HBeAg seroclearance (years) Numbers at risk 




221                    216                       183                       72                        18                         4  
324                    320                       301                      195                       83                        29                        1 
178                    169                       159                      107                       46                        26                        2   
HBeAg seroclearance >40 years 
HBeAg seroclearance 30-40 years 
HBeAg seroclearance <30 years 
P<0.001 
Time after HBeAg seroclearance (years) 
Group 1. Normal ALT 
Group 2. Normal ALT & ALT <3x ULN 
Group 3. Normal ALT with flares  
Group 4. Persistently abnormal ALT 
Numbers at risk 




 25                         22                         19                          9                          3                          1                              
305                      300                       267                      140                        46                        20                         3 
320                      318                       307                      198                        91                        39     
 73                         65                         50                         28                         7                        
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